Try as we might, we can’t cover all the fascinating biotech news out there! Here’s a roundup of what didn’t make the cut over the last week.
Policy and legal
- The Polish biotech Selvita announced it will separate into two separate companies one focusing on its oncology therapeutics pipeline and one on its contract research business.
- French bioplastics company Carbios was granted a US patent for its PET plastic recycling technology.
- MaSTherCell, a cell and gene therapy company in Belgium, announced it will open a large new commercial manufacturing facility for cell & gene therapies, which is expected to open in 2021.
- Dutch immuno-oncology biotech Glycostem Therapeutics will partner with Phio Pharmaceuticals to make novel anti-cancer drugs using the US-biotech’s RNAi technology ands natural killer cells.
- Belgian Barc Labs and Spanish OWL Metabolics will partner to combine lab services and metabolic technology to help develop new therapeutics for the liver condition non-alcoholic steatohepatitis.
- French Transgene and Swedish BioInvent will extend an existing collaboration to develop oncolytic viruses for treating solid tumors.
- University of London spin-out Domainex, along with researchers in Belfast, has discovered new anticancer candidate drugs that target a protein called FLIP that could be used to treat blood, breast and lung cancer.
Regulations and funding
- Irish and English biotech partners Valitacell and Solentim obtained €3.5M funding to help develop new biologics and cell therapies.
- Kymriah, a CAR T-cell therapy developed by Novartis, has been given marketing approval in Japan, the first such therapy to be approved in Asia.
- German biotech Cytena received €3M in series A funding to progress its single cell isolation and analysis technology.
- Synerkine Pharma, a Dutch biotech focusing on treating chronic pain, closed a €3.3M series A round.
- UK-Irish Inflazome received more than €890,000 funding from The Michael J. Fox Foundation to go towards its research into treating Parkinson’s disease.
- Italian biotech Cassiopea announced positive phase III results, for both efficacy and safety, for its acne treatment clascoterone when taken for up to a year.
Images via E. Resko